PMA
P210002: therascreen PDGFRA RGQ PCR Kit
FDA PMA · Somatic gene mutation detection system · QIAGEN GmbH
Key facts
| PMA number | P210002 |
|---|---|
| Trade name | therascreen PDGFRA RGQ PCR Kit |
| Generic name | Somatic gene mutation detection system |
| Applicant | QIAGEN GmbH |
| Owner/operator | QIAGEN, GmbH |
| Product code | OWD |
| Approval date | Jun 29, 2023 |
| Docket number | 23M-3451 |
| Notice date | Aug 18, 2023 |
| Establishment registration | 3004013603 |
| FEI number | 3004013603 |
At a glance
- None Supplements
- Jun 29, 2023 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: